Maxygen hematology, other news

Maxygen said its shareholders approved a plan previously approved by Maxygen's board to liquidate and dissolve the company. The initial shareholder payout is about $69.5 million, or about $2.50 per share. Maxygen said it could make one or more additional liquidating distributions totaling up to $0.09 per share. The company filed a certificate of dissolution. NASDAQ also suspended trading of the stock on Aug. 29 and advised Maxygen that it will file a Form 25 with the SEC to delist the stock from the exchange. At June 30, the company had $79.4 million in cash and a six-month operating loss of $5.1 million (see BioCentury, June 17). ...